Efficacy of the Phosphodiesterase-4 Inhibitor, Apremilast, in a Patient with Severe Alopecia Areata

    August 2019 in “ European Journal of Dermatology ”
    Moe Sakakibara, Harunari Shimoyama, Mami Nomura … Yoshihiro Kuwano
    Studysummary This abstract provides no new clinical results; it discusses the role of surgery and interventional radiotherapy in treating cutaneous squamous cell carcinoma.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on stm.cairn.info →
    Discuss this study in the Community →

    Research cited in this study 4

    1. A Randomized Placebo-Controlled Single-Center Pilot Study of the Safety and Efficacy of Apremilast in Subjects with Moderate-to-Severe Alopecia Areata Archives of dermatological research · 2018
    2. Lack of Efficacy of Apremilast in 9 Patients with Severe Alopecia Areata Journal of the American Academy of Dermatology · 2017
    3. The PDE4 Inhibitor, Apremilast, Suppresses Experimentally Induced Alopecia Areata in Human Skin In Vivo Journal of Dermatological Science · 2014
    4. Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition Nature medicine · 2014

    Related research 2

    1. Comparing the Efficacy of Oral Apremilast, Intralesional Corticosteroids, and Their Combination in Patients With Patchy Alopecia Areata: A Randomized Clinical Controlled Trial Archives of Dermatological Research · 2024
    2. Twenty Nail Dystrophy with Alopecia Areata in an Atopic Child International journal of research in dermatology · 2019